Literature DB >> 20554204

Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.

Geraint B Rogers1, Lucas R Hoffman, Marvin Whiteley, Thomas W V Daniels, Mary P Carroll, Kenneth D Bruce.   

Abstract

As a new generation of culture-independent analytical strategies emerge, the amount of data on polymicrobial infections will increase dramatically. For these data to inform clinical thinking, and in turn to maximise benefits for patients, an appropriate framework for their interpretation is required. Here, we use cystic fibrosis (CF) lower airway infections as a model system to examine how conceptual and technological advances can address two clinical questions that are central to improved management of CF respiratory disease. Firstly, can markers of the microbial community be identified that predict a change in infection dynamics and clinical outcomes? Secondly, can these new strategies directly characterize the impact of antimicrobial therapies, allowing treatment efficacy to be both assessed and optimized? Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554204      PMCID: PMC3034215          DOI: 10.1016/j.tim.2010.04.005

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  73 in total

1.  Defining a pulmonary exacerbation in cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; J Williams-Warren; M Pepe; A Smith; A B Montgomery; B Ramsey
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

2.  The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples.

Authors:  G B Rogers; P Marsh; A F Stressmann; C E Allen; T V W Daniels; M P Carroll; K D Bruce
Journal:  Clin Microbiol Infect       Date:  2010-11       Impact factor: 8.067

Review 3.  Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity.

Authors:  Geraint B Rogers; Franziska A Stressmann; Alan W Walker; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2010-03       Impact factor: 5.225

4.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

Authors:  Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

Review 5.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

6.  Mutation in the relA gene of Vibrio cholerae affects in vitro and in vivo expression of virulence factors.

Authors:  Shruti Haralalka; Suvobroto Nandi; Rupak K Bhadra
Journal:  J Bacteriol       Date:  2003-08       Impact factor: 3.490

7.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

Authors:  Arnold L Smith; Stanley B Fiel; Nicole Mayer-Hamblett; Bonnie Ramsey; Jane L Burns
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

8.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

9.  Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling.

Authors:  G B Rogers; C A Hart; J R Mason; M Hughes; M J Walshaw; K D Bruce
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 10.  Ibis T5000: a universal biosensor approach for microbiology.

Authors:  David J Ecker; Rangarajan Sampath; Christian Massire; Lawrence B Blyn; Thomas A Hall; Mark W Eshoo; Steven A Hofstadler
Journal:  Nat Rev Microbiol       Date:  2008-06-03       Impact factor: 60.633

View more
  30 in total

1.  Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.

Authors:  William G Flight; Ann Smith; Christopher Paisey; Julian R Marchesi; Matthew J Bull; Phillip J Norville; Ken J Mutton; A Kevin Webb; Rowland J Bright-Thomas; Andrew M Jones; Eshwar Mahenthiralingam
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 3.  Enhancing the utility of existing antibiotics by targeting bacterial behaviour?

Authors:  Geraint B Rogers; Mary P Carroll; Kenneth D Bruce
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Differential response of Streptococcus mutans towards friend and foe in mixed-species cultures.

Authors:  Jinman Liu; Chenggang Wu; I-Hsiu Huang; Justin Merritt; Fengxia Qi
Journal:  Microbiology (Reading)       Date:  2011-05-12       Impact factor: 2.777

5.  A quantitative analysis of Ureaplasma urealyticum and Ureaplasma parvum compared with host immune response in preterm neonates at risk of developing bronchopulmonary dysplasia.

Authors:  Matthew S Payne; Kevin C W Goss; Gary J Connett; Julian P Legg; Ken D Bruce; Vicki Chalker
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

6.  Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa.

Authors:  Kate B Twomey; Oisin J O'Connell; Yvonne McCarthy; J Maxwell Dow; George A O'Toole; Barry J Plant; Robert P Ryan
Journal:  ISME J       Date:  2011-12-01       Impact factor: 10.302

Review 7.  Interactions between Pseudomonas aeruginosa and Staphylococcus aureus during co-cultivations and polymicrobial infections.

Authors:  Angela T Nguyen; Amanda G Oglesby-Sherrouse
Journal:  Appl Microbiol Biotechnol       Date:  2016-05-28       Impact factor: 4.813

Review 8.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 9.  Emperor's new clothes: Is particle disease really infected particle disease?

Authors:  Marcin K Wasko; Stuart B Goodman
Journal:  J Orthop Res       Date:  2016-05-30       Impact factor: 3.494

10.  Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli.

Authors:  Kimberly A Kline; Drew J Schwartz; Nicole M Gilbert; Scott J Hultgren; Amanda L Lewis
Journal:  Infect Immun       Date:  2012-09-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.